SK Biopharmaceuticals files US NDA for liquid Cenobamate

SK Biopharmaceuticals announced that it submitted a new drug application to the US Food and Drug Administration for the oral suspension formulation of its epilepsy drug Cenobamate. In addition to the existing tablet form, this NDA seeks approval for a liquid option for adult patients with partial-onset seizures. The liquid-form oral suspension aims to enhance convenience for patients who have difficulty swallowing tablets, offering flexible administration based on patient needs.